P-0204 - Comparison of Cetuximab and Bevacizumab as First-line Treatment in KRAS Wild Type Advanced Colorectal Cancer Patients: A Retrospective Analysis

Date 28 June 2014
Event World GI 2014
Session Poster Session
Topics Anti-Cancer Agents & Biologic Therapy
Colon Cancer
Rectal Cancer
Presenter Qian Zhang
Citation Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165
Authors Q. Zhang1, T. Yau1, R. Leung1, H. Wong1, J. Chiu1, W. Chu Kin2, J. Poon1, L. Kwong Yok1
  • 1Queen Mary Hospital, Hong Kong/CN
  • 2Colorectal and Laparoscopic Surgery Center, Hong Kong/CN



Cetuximab and bevacizumab-based therapies have been demonstrated to improve survival outcomes as first-line treatment in KRAS wild-type metastatic colorectal cancer (mCRC) patients. However, few studies have evaluated any difference in treatment outcomes between cetuximab and bevacizumab-based therapies as first-line treatment for KRAS wild-type mCRC patients.


Between 2008 to 2012, KRAS wild type mCRC patients who received cetuximab-containing or bevacizumab-containing regimens as first-line treatment for mCRC at Queen Mary Hospital, Hong Kong were reviewed. Overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) were assessed as the study endpoints in the analysis.


Fifty patients were included in the analysis. Among these patients, 35 patients were treated by cetuximab-based treatment and the remaining 15 patients were by bevacizumab-based therapy. The median age in cetuximab group is 57 years versus 69 years in bevacizumab group (p = 0.69). In cetuximab-based treatment, both fluoropyrimidine (100%) and oxaliplatin (63%) were the commonly used chemotherapy backbone. Likewise, in bevacizumab-based therapy, fluoropyrimidine (93%) and oxaliplatin (53%) were used to combine with bevacizumab. ORR was seemingly higher in cetuximab arm (77.8%) as compared to bevacizumab arm (53.3%), though not statistically significant (odds ratio 3.07, p = 0.08). Similar median PFS (9.6 months vs. 9.7 months, hazard ratio 0.78, p = 0.526) and median OS (27.5 months vs. 27.4 months, hazard ratio 0.92, p = 0.843) were reported between cetuximab-based and bevacizumab-based therapies. Second-line therapy was given in 82.9 and 80% of patients treated by upfront cetuximab-based and bevacizumab based treatment, respectively.


Comparable ORRs, PFS and OS were observed, which might suggests similar efficacy and survival outcomes of upfront cetuximab-based and bevacizumab-based chemotherapies in treating KRAS wild-type mCRC patients.